FOR IMMEDIATE RELEASE

 

Contacts:
Michael Christiano, AVEO Pharmaceuticals, Inc.
(617) 299-5925

 

Caton Lovett, Pure Communications
(910) 509-3975

 

AVEO Pharmaceuticals to Present at the
Third Annual JMP Securities Healthcare Focus Conference

CAMBRIDGE, Mass., September 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Third Annual JMP Securities Healthcare Focus Conference on Tuesday, October 7, 2008 at 3:00 p.m. (ET) at the Le Parker Meridien in New York City.

 

About AVEO
AVEO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at www.aveopharma.com.